Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2019-04-04 AGM Information
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
OXUR AGM_EGM 07MAY19 ConveningNotice (Dutch).pdf
AGM Information Classification · 99% confidence The document is explicitly titled 'OPROEPING TOT DE JAARVERGADERING EN DE BUITENGEWONE ALGEMENE VERGADERING VAN AANDEELHOUDERS' (Notice of the Annual General Meeting and the Extraordinary General Meeting of Shareholders). It details the agenda for both meetings, including proposals for statutory changes (related to the new Belgian Companies Code) and capital authorizations. The presence of both the Annual Meeting (AGM) agenda and the Extraordinary Meeting agenda, along with detailed proposals for shareholder votes, strongly indicates this document serves as the official notice and material for the AGM. This aligns perfectly with the definition of AGM-R (AGM Information), which covers presentations and materials shared during the AGM. Although it contains elements that might relate to other filings (like remuneration report discussion, which touches on DEF 14A, or capital changes, which touches on CAP), the primary purpose and context is the convening and setting the agenda for the Annual General Meeting.
2019-04-04 Dutch
Annual Report - financial information 2018.pdf
Annual Report Classification · 100% confidence The document is a comprehensive annual report for Oxurion NV for the fiscal year ending December 31, 2018. It contains a table of contents listing sections such as the Management Report, Corporate Governance, Consolidated Financial Statements, and the Statutory Auditor's Report. The document length is substantial, and it provides full financial disclosures and management analysis, fitting the definition of an Annual Report (10-K equivalent for non-US entities). FY 2018
2019-04-04 English
Jaarverslag - financiële informatie 2018.pdf
Annual Report Classification · 100% confidence The document is explicitly titled 'Jaarverslag' (Annual Report) and contains comprehensive sections including a CEO foreword, management report, corporate governance, consolidated financial statements (balance sheet, income statement, cash flow), and the auditor's report. It covers the full fiscal year ending December 31, 2018. Given the length and the inclusion of full financial statements, it is classified as an Annual Report (10-K equivalent). FY 2018
2019-04-04 Dutch
OXUR BU FY18 070319 EN FIN.pdf
Management Reports Classification · 95% confidence The document is a 'Business Update' for the fiscal year 2018, released on March 7, 2019. It provides a comprehensive overview of the company's clinical pipeline, corporate developments, and financial highlights (including revenue and cash position). While it contains financial data, it is structured as a narrative business update rather than a formal, audited 10-K or a standard quarterly financial report. Given the detailed management commentary on business trends, clinical trial progress, and outlook, it aligns best with the Management Reports (MDA) category, which covers management's detailed explanation of financial results and business outlook. FY 2018
2019-03-07 English
OXUR BU FY18 070319_NL FIN.pdf
Audit Report / Information Classification · 95% confidence The document is titled "Oxurion NV Business Update – Boekjaar 2018" and is dated March 7, 2019. It provides a comprehensive review of the company's financial performance for the year ended December 31, 2018, including revenue, total income, and cash position as of year-end. It also details significant business developments, management changes, and updates on the clinical pipeline (Phase 1/2 trial results, enrollment status, expected readouts). This structure—covering full-year financial highlights, operational achievements, and strategic updates—is characteristic of an Annual Report or a detailed business update that often accompanies or precedes the formal 10-K filing, but given the context of a 'Business Update' for the full year, it functions as the primary annual disclosure of performance and strategy. Since it contains detailed financial figures for the full year (2018) and is not explicitly labeled as a 10-K, but serves the function of an annual review, it aligns best with the comprehensive nature of an Annual Report (10-K) or a very detailed Interim/Quarterly Report (IR) if it were only for a shorter period. However, because it explicitly covers the 'Boekjaar 2018' (Fiscal Year 2018) and includes full-year financials, it is classified as the Annual Report (10-K) equivalent, or the closest comprehensive annual disclosure available in the provided codes. If it were a short announcement *about* the 10-K, it would be RPA, but the text is extensive and contains the substance of the annual review. FY 2018
2019-03-07 Dutch
OXUR BU Q3 FY18 EN Final.pdf
Earnings Release Classification · 98% confidence The document is explicitly titled "PRESS RELEASE" and is dated October 19, 2018, providing a "Business Update – Q3 2018". It details operational milestones (clinical trial enrollments, rebranding) and key financial figures (€95.1 million cash position) for the three-month period ending September 30, 2018. This structure—a press release summarizing quarterly performance highlights, pipeline progress, and cash position—is the defining characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim/Quarterly Report (IR), but rather the initial announcement of the period's results. Q3 2018
2018-10-19 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.